Abstract:Aim To evaluate the effects of ezetimibe co-administered with statins vs statins dose-doubling on major adverse cardiovascular events in patients with coronary heart disease systematically, in order to provide evidence-based reference for clinical use. Methods The pertinent randomized controlled trials (RCTs) about ezetimibe co-administered with statins trail group and statins dose-doubling control group in the treatment of coronary heart disease were retrieved from The Cochrane Library, PubMed, Embase, CNKI, CSTJ, CBMdisc and Wan fang Database. The quality of included studies were evaluated according to modified Jadad quality scale after extracting data. Meta-analysis was performed by using RevMan 5.3 statistical software. Results A total of 30 RCTs were included,involving 4 757 patients. The results of Meta-analysis showed that compared with double-dose statins, ezetimibe-plus-statins markedly decrease major adverse cardiovascular events(P=0.03), angina(P<0.001) and myocardial infarction(P<0.001); the incidence of cardiac death, revascularization, heart failure and stroke had no significant difference in two groups; ezetimibe-plus-statins significantly decrease adverse reactions, such as transaminase elevation(P<0.001), creatine kinase elevation(P=0.02), and muscle pain, muscle weakness and other muscle injuries(P<0.001). Meta-analysis in subgroup was studied according to the kinds and dosage of statins and follow-up time, compared with atorvastatin 40 mg, ezetimibe 10 mg plus atorvastatin 20 mg showed more advantages in reducing the incidence of major adverse cardiovascular events and myocardial infarction than other subgroups. However, no effect was found on the results between a long follow-up time (≥6 months) with a short follow-up time (≤3 months). Conclusions For patients with coronary heart disease, statins combined with ezetimibe has a significant benefit in myocardial infarction and angina compared with double dose statins, but the benefit of cardiac death and stroke were not found. The incidence of adverse reactions is significantly reduced.